Ripretinib in patients with advanced gastrointestinal stromal tumours (INVICTUS): a double-blind, randomised, placebo-controlled, phase 3 trial.

The Lancet Oncology
Jean-Yves BlayMargaret von Mehren

Abstract

Resistance to approved inhibitors of KIT proto-oncogene, receptor tyrosine kinase (KIT), and platelet-derived growth factor receptor α (PDGFRA) is a clinical challenge for patients with advanced gastrointestinal stromal tumours. We compared the efficacy and safety of ripretinib, a switch-control tyrosine kinase inhibitor active against a broad spectrum of KIT and PDGFRA mutations, with placebo in patients with previously treated, advanced gastrointestinal stromal tumours. In this double-blind, randomised, placebo-controlled, phase 3 study, we enrolled adult patients in 29 specialised hospitals in 12 countries. We included patients aged 18 years or older who had advanced gastrointestinal stromal tumours with progression on at least imatinib, sunitinib, and regorafenib or documented intolerance to any of these treatments despite dose modifications, and who had an Eastern Cooperative Oncology Group (ECOG) performance status of 0-2. Eligible patients were randomly assigned (2:1) to receive either oral ripretinib 150 mg once daily (ripretenib group) or placebo once daily (placebo group). Randomisation was done via an interactive response system using randomly permuted block sizes of six and stratified according to number of previous...Continue Reading

References

Dec 4, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Michael C HeinrichJonathan A Fletcher
Jun 2, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Christopher L CorlessMichael C Heinrich
Mar 23, 2006·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Eva WardelmannPeter Hohenberger
Sep 7, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Michael C HeinrichJonathan A Fletcher
Jul 16, 2008·The Journal of Pathology·B LieglJ A Fletcher
Oct 29, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Michael C HeinrichGeorge D Demetri
Jan 24, 2009·Proceedings of the National Academy of Sciences of the United States of America·Ketan S GajiwalaGeorge D Demetri
Feb 4, 2011·Annals of Oncology : Official Journal of the European Society for Medical Oncology·O DudeckD Pink
Sep 23, 2014·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Andrew P GarnerVictor M Rivera
Mar 17, 2015·Journal of the American Academy of Dermatology·Bianca Maria PiracciniEmi Dika
Sep 21, 2015·Annals of Oncology : Official Journal of the European Society for Medical Oncology·V R BelumM E Lacouture
Apr 14, 2016·The Lancet Oncology·Olivier MirUNKNOWN PAZOGIST study group of the French Sarcoma Groupe-Groupe d'Etude des Tumeurs Osseuses (GSF-GETO)
Apr 1, 2017·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Paolo G CasaliUNKNOWN European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group, Italian Sarcoma Group, and Au
Jul 25, 2017·Journal of Gastrointestinal Oncology·Peter J OppeltBrian A Van Tine
Aug 14, 2018·Annals of Oncology : Official Journal of the European Society for Medical Oncology·M L HemmingS George
Oct 31, 2018·American Journal of Clinical Dermatology·Mario Lacouture, Vincent Sibaud

❮ Previous
Next ❯

Citations

May 29, 2020·Current Treatment Options in Oncology·Sheima FaragRobin L Jones
Aug 18, 2020·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Filip JankuSuzanne George
Jun 25, 2020·Drugs·Sohita Dhillon
Sep 26, 2020·International Journal of Molecular Sciences·Azadeh AmirnasrErik A C Wiemer
Jul 1, 2020·Expert Opinion on Drug Metabolism & Toxicology·Gloria RavegniniSabrina Angelini
Jun 27, 2020·Nature Reviews. Gastroenterology & Hepatology·Katrina Ray
Oct 14, 2020·EMBO Molecular Medicine·Thomas Gp GrünewaldDominique Heymann
Dec 15, 2020·Expert Opinion on Pharmacotherapy·Antoine Italiano
Jul 1, 2020·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·César Serrano, Suzanne George
Jan 30, 2021·Deutsche medizinische Wochenschrift·Peter Reichardt, Daniel Pink
Feb 3, 2021·Diagnostics·Iva BrčićBernadette Liegl-Atzwanger
Jan 22, 2021·Therapeutic Advances in Medical Oncology·M Julia Lostes-BardajiCésar Serrano
Jan 10, 2021·International Journal of Molecular Sciences·Christos VallilasMichalis V Karamouzis
Nov 18, 2020·International Journal of Molecular Sciences·Jorge Esteban-VillarrubiaJavier Molina-Cerrillo
Jan 7, 2021·Journal of Hematology & Oncology·Ciara M KellyPing Chi
Oct 29, 2020·Journal of Hematology & Oncology·Liling HuangYuankai Shi
Mar 2, 2021·Expert Opinion on Emerging Drugs·Daniel F Pilco-JanetaCésar Serrano
Mar 3, 2021·Drugs & Aging·Monika Dudzisz-ŚledźPiotr Rutkowski
Mar 7, 2021·Cancers·Jonas Cicenas, Asta Račienė
Mar 1, 2021·Current Treatment Options in Oncology·David Gómez-PeregrinaCésar Serrano
Mar 21, 2021·Current Treatment Options in Oncology·Jennifer A YonkusTravis E Grotz
Mar 20, 2021·Nature Reviews. Disease Primers·Jean-Yves BlayMargaret von Mehren
Apr 3, 2021·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Lillian R KlugMichael C Heinrich
Apr 18, 2021·Naunyn-Schmiedeberg's Archives of Pharmacology·Gizem Kayki-Mutlu, Martin C Michel
Apr 30, 2021·Therapeutic Innovation & Regulatory Science·Catherine FengEric T-K Mui
Apr 28, 2021·European Journal of Medicinal Chemistry·Xiaoxia LiangBo Jing
May 6, 2021·Therapeutic Advances in Gastroenterology·John R Zalcberg
May 15, 2021·Bulletin du cancer·Sarah Watson
Apr 20, 2021·Current Opinion in Oncology·César Serrano
Jun 23, 2021·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Birgit GeoergerLynley V Marshall
Aug 4, 2021·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Yoon-Koo KangSebastian Bauer
Aug 10, 2021·Biochimica Et Biophysica Acta. Reviews on Cancer·Fan TangXia-Wei Wei
Aug 19, 2021·Expert Review of Anticancer Therapy·Miguel Henriques-Abreu, César Serrano
Aug 21, 2021·Bioorganic & Medicinal Chemistry·Thais Cristina Mendonça Nogueira, Marcus Vinicius Nora de Souza
Aug 15, 2021·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Suzanne GeorgeFilip Janku

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.